Pharmacodynamic Variability beyond That Explained by MICs

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Use of Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Phase 2 and 3 Dosing Strategies for Doripenem2005 · 123 citations
2. 2Population Pharmacokinetics of Doripenem Based on Data from Phase 1 Studies with Healthy Volunteers and Phase 2 and 3 Studies with Critically Ill Patients2010 · 46 citations
3. 3Pharmacokinetic-Pharmacodynamic-Model-Guided Doripenem Dosing in Critically Ill Patients2010 · 53 citations
4. 4<i>In Vivo</i>Efficacy of Simulated Human Dosing Regimens of Prolonged-Infusion Doripenem against Carbapenemase- Producing<i>Klebsiella pneumoniae</i>2010 · 52 citations
5. 5In Vivo Efficacy of 1- and 2-Gram Human Simulated Prolonged Infusions of Doripenem against <i>Pseudomonas aeruginosa</i>2009 · 32 citations